Art. 1 Regulation (EU) 2024/2699

Subject matter

In forcesince 18 Oct 2024

This Regulation lays down detailed procedural rules concerning cooperation, in the form of exchange of information, of the Member State Coordination Group on Health Technology Assessment (‘Coordination Group’), with the facilitation of the secretariat of the Coordination Group (‘the HTA secretariat’), with the European Medicines Agency on the joint clinical assessment and joint scientific consultation referred to in Articles 7 to 21 of Regulation (EU) 2021/2282 as regards:

(a)

planning and forecast of the joint clinical assessments and joint scientific consultations;

(b)

identification of patients, clinical experts and other relevant experts (‘individual experts’) to be involved in joint clinical assessments and joint scientific consultations;

(c)

horizontal scientific and technical matters related to joint clinical assessment and joint scientific consultation;

(d)

security of sharing and protection of confidential information exchanged between the European Medicines Agency and the HTA secretariat and then shared by the HTA secretariat with the Coordination Group or its subgroups and their members within the context of joint clinical assessment and joint scientific consultation.